Statins associated with lower risk of death from pneumonia

Oct 27, 2008

Individuals who take cholesterol-lowering statins before being hospitalized with pneumonia appear less likely to die within 90 days afterward, according to a report in the October 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

In the United States and Europe, pneumonia hospitalization rates have increased 20 percent to 50 percent over the past decade, according to background information in the article. About 10 percent to 15 percent of those with pneumonia die from the disease. A recent review article indicated that statins may benefit patients with sepsis (infection of the bloodstream) or bacteremia (presence of bacteria in the bloodstream), possibly due to the medications' anti-clotting, anti-inflammatory or immune-modifying properties.

Reimar W. Thomsen, M.D., Ph.D., of Aarhus University and Aalborg Hospital, Aalborg, Denmark, and colleagues reviewed data from 29,900 adults hospitalized with pneumonia between 1997 and 2004. Of these, 1,371 (4.6 percent) were taking statins at the time.

"Mortality [death] among statin users was lower than among non-users: 10.3 percent vs. 15.7 percent after 30 days and 16.8 percent vs. 22.4 percent after 90 days," the authors write. The lowest relative death rate associated with statins was observed in patients older than 80 and in those with bacteremia. "The differences became apparent during the first few weeks of hospitalization, a period associated with a high number of pneumonia-related deaths, and they increased only minimally between 30 and 90 days after admission, which suggests that statin use is beneficial primarily in the early phase of infection."

Previous statin use, or the use of any other preventive medication for cardiovascular health, was not associated with a reduced death rate from pneumonia.

"Several biological mechanisms may explain our results," the authors write. Statins change the immune response, beneficially affect processes associated with blood clotting and inflammation and inhibit dysfunction in blood vessels. These effects may especially benefit patients with sepsis and bacteremia, which are associated with early death from pneumonia.

"Our study adds to the accumulating evidence that statin use is associated with improved prognosis after severe infections," the authors write. "The decrease in mortality associated with statin use seems to be substantial in patients with pneumonia requiring hospital admission. Randomized trials are needed to examine causality of the associations found in observational studies. Given the availability of statins, with their relatively low cost and mild adverse effects, positive results of statin therapy trials in patients with pneumonia would have substantial clinical and public health implications."

Citation: Arch Intern Med. 2008;168[19]:2081-2087. www.jamamedia.org

Source: JAMA and Archives Journals

Explore further: Nigeria death shows Ebola can spread by air travel

add to favorites email to friend print save as pdf

Related Stories

A tiny, time-released treatment

Oct 09, 2013

Omid Farokhzad's vision of medicine's future sounds a lot like science fiction. He sees medicine scaled down, with vanishingly small nanoparticles playing a big role, delivering drug doses measured in molecules ...

Recommended for you

Global impact of the Ebola outbreak

16 minutes ago

The Ebola virus has been spreading in West Africa since March, but the current outbreak over the past few weeks has reached new heights and elevated the crisis. More than 650 people have died, and in recent days it was learned ...

S.Korea detects second foot-and-mouth case

2 hours ago

South Korea on Monday reported its second case of foot-and-mouth disease in less than a week, triggering fearful memories of a devastating 2011 outbreak that forced the culling of millions of livestock.

Ebola kills Liberian doctor, 2 Americans infected

3 hours ago

(AP)—One of Liberia's most high-profile doctors has died of Ebola, officials said Sunday, and an American physician was being treated for the deadly virus, highlighting the risks facing health workers trying ...

Hepatitis C virus genotype 1 is most prevalent worldwide

3 hours ago

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journa ...

1 in 3000 blood donors in England infected with hepatitis E

3 hours ago

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Oct 28, 2008
Looking at overall mortality; no, that's NO, that's zero studies have ever shown any benefit for women at any age and benefits for men are close to insignificant except immediately after an "event", coupled w/ expiring patents, the manufacturers are scraping the bottom of the barrel to find ways to extend their windfall profits. Again, follow the money.